# R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

> **NCT01133158** · PHASE2 · COMPLETED · sponsor: **Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea** · enrollment: 61 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Rituximab, Bendamustine, Mitoxantrone, Dexamethasone

## Key facts

- **NCT ID:** NCT01133158
- **Lead sponsor:** Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2013-12
- **Final completion:** 2016-07
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01133158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01133158, "R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01133158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*